Advice
In the absence of a submission from the holder of the marketing authorisation:
botulinum toxin type A (Azzalure®) is not recommended for use within NHS Scotland.
Indication under review: for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical “frown” lines between the eyebrows) in adult patients under 65 years and younger, when the severity of these lines has an important psychological impact on the patient.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication due to its cosmetic nature. As a result we cannot recommend its use within NHSScotland.
Download detailed advice70KB (PDF)
Medicine details
- Medicine name:
- botulinum toxin Type A (Azzalure)
- SMC ID:
- 679/11
- Indication:
- For the temporary improvement in the appearance of moderate to severe glabellar lines (vertical “frown†lines between the eyebrows) in adult patients under 65 years and younger, when the severity of these lines has an important psychological impact on the patient.
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 17 January 2011